These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 17721093

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 3. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, Horn PS.
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
    Dahari H, Affonso de Araujo ES, Haagmans BL, Layden TJ, Cotler SJ, Barone AA, Neumann AU.
    J Hepatol; 2010 Sep; 53(3):460-7. PubMed ID: 20561702
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S.
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [Abstract] [Full Text] [Related]

  • 10. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
    Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti M, Fauci AS, Polis MA, Kottilil S.
    J Acquir Immune Defic Syndr; 2009 Dec 01; 52(4):452-8. PubMed ID: 19797971
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF, Sun HQ, Huang Q, Wang JR, Zhang XX, Liu XN, Ma Q, Lu HZ.
    Haemophilia; 2010 May 01; 16(3):502-7. PubMed ID: 20028427
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B, CORAL-1 study group.
    J Viral Hepat; 2007 Oct 01; 14(10):704-13. PubMed ID: 17875005
    [Abstract] [Full Text] [Related]

  • 13. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M, Tural C, Papagno L, Garcia E, Jou A, Bofill M, Autran B, Clotet B, Blanco J.
    Antivir Ther; 2010 Oct 01; 15(3):333-42. PubMed ID: 20516553
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C.
    J Viral Hepat; 2008 Jul 01; 15(7):482-9. PubMed ID: 18221297
    [Abstract] [Full Text] [Related]

  • 17. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ, Horn PS, Rouster SD, Stanford S, Eyster ME, Sherman KE, Multicenter Hemophilia Cohort HCV Study Group.
    Hepatology; 2006 Nov 01; 44(5):1146-57. PubMed ID: 17058240
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
    Rivero-Juárez A, Lopez-Cortes LF, Camacho A, Torres-Cornejo A, Pineda JA, Marquez-Solero M, Caruz A, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.
    PLoS One; 2012 Nov 01; 7(11):e48959. PubMed ID: 23145040
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.